Free Trial
NASDAQ:IMCR

Immunocore (IMCR) Stock Price, News & Analysis

Immunocore logo
$29.32 -0.32 (-1.08%)
Closing price 04:00 PM Eastern
Extended Trading
$29.30 -0.02 (-0.09%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Immunocore Stock (NASDAQ:IMCR)

Key Stats

Today's Range
$29.03
$30.04
50-Day Range
$28.20
$33.00
52-Week Range
$27.19
$66.00
Volume
165,908 shs
Average Volume
436,082 shs
Market Capitalization
$1.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.64
Consensus Rating
Moderate Buy

Company Overview

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Remove Ads

Immunocore Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

IMCR MarketRank™: 

Immunocore scored higher than 37% of companies evaluated by MarketBeat, and ranked 709th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 8 buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Immunocore has only been the subject of 3 research reports in the past 90 days.

  • Read more about Immunocore's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunocore are expected to decrease in the coming year, from ($0.94) to ($1.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunocore is -30.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunocore is -30.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunocore has a P/B Ratio of 3.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immunocore's valuation and earnings.
  • Percentage of Shares Shorted

    16.81% of the float of Immunocore has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunocore has a short interest ratio ("days to cover") of 28.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunocore has recently increased by 0.13%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Immunocore does not currently pay a dividend.

  • Dividend Growth

    Immunocore does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.81% of the float of Immunocore has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunocore has a short interest ratio ("days to cover") of 28.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunocore has recently increased by 0.13%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Immunocore has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Immunocore this week, compared to 5 articles on an average week.
  • Search Interest

    Only 2 people have searched for IMCR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Immunocore to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunocore insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,994,085.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 9.10% of the stock of Immunocore is held by insiders.

  • Percentage Held by Institutions

    84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunocore's insider trading history.
Receive IMCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.

IMCR Stock News Headlines

Elon Musk is helping print “new gold”
MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.
Immunocore (NASDAQ:IMCR) Shares Gap Up on Insider Buying Activity
HC Wainwright Reaffirms Buy Rating for Immunocore (NASDAQ:IMCR)
Immunocore reports promising HIV trial results
See More Headlines

IMCR Stock Analysis - Frequently Asked Questions

Immunocore's stock was trading at $29.50 on January 1st, 2025. Since then, IMCR shares have decreased by 1.3% and is now trading at $29.1050.
View the best growth stocks for 2025 here
.

Immunocore Holdings plc (NASDAQ:IMCR) posted its quarterly earnings results on Wednesday, November, 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.50. The firm's revenue was up 23.7% on a year-over-year basis.

Immunocore (IMCR) raised $199 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,300,000 shares at $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO.

Immunocore's top institutional investors include T. Rowe Price Investment Management Inc. (13.39%), Wellington Management Group LLP (13.23%), FMR LLC (9.63%) and Primecap Management Co. CA (5.33%). Insiders that own company stock include Bros Advisors Lp Baker and Leger Tina Amber St.
View institutional ownership trends
.

Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunocore investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/06/2024
Today
3/25/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMCR
Fax
N/A
Employees
320
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$65.64
High Stock Price Target
$100.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+121.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.54
Research Coverage
13 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-55,290,000.00
Pretax Margin
-18.14%

Debt

Sales & Book Value

Annual Sales
$310.20 million
Price / Cash Flow
N/A
Book Value
$7.42 per share
Price / Book
3.99

Miscellaneous

Free Float
45,480,000
Market Cap
$1.48 billion
Optionable
Optionable
Beta
0.79
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:IMCR) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners